Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03471351 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
A Phase 1 study, sponsored by Rhizen Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03471351: Clinical Trial Phase 1 study, sponsored by Rhizen Pharmaceuticals.
NCT03471351 is a Phase 1 study that was terminated before completion, run by Rhizen Pharmaceuticals. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03471351, a Phase 1 study, was terminated before completion, sponsored by Rhizen Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL.
Primary Outcome
The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle of treatment.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Tenalisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-07-18 |
| Est. Completion | 2019-02-13 |
| Phase | Phase 1 |
Why NCT03471351 stopped before completion
NCT03471351 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03471351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03471351 about?
NCT03471351 is a clinical study titled "Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL". To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL.
What is the current status of trial NCT03471351?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2018-07-18. Estimated completion is 2019-02-13.
What interventions are being tested in trial NCT03471351?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Tenalisib (DRUG).
Who is sponsoring clinical trial NCT03471351?
This trial is sponsored by Rhizen Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03471351's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI